Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
25 août 2023 16h10 HE
|
Aclarion, Inc.
BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
08 juin 2023 07h30 HE
|
Aclarion, Inc.
Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually. The International Society for the Advancement...
Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
23 mai 2023 07h30 HE
|
Aclarion, Inc.
Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy Aclarion to Participate in...
Aclarion, Inc. Announces Delayed 10-Q Filing
23 mai 2023 07h00 HE
|
Aclarion, Inc.
BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
19 mai 2023 07h30 HE
|
Aclarion, Inc.
Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of...
Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain
02 mai 2023 07h00 HE
|
Aclarion, Inc.
Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market,...
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial
24 avr. 2023 07h00 HE
|
Aclarion, Inc.
Success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over...
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
15 févr. 2023 07h00 HE
|
Aclarion, Inc.
NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a...